MCID: LPS002
MIFTS: 55

Liposarcoma malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Liposarcoma

Aliases & Descriptions for Liposarcoma:

Name: Liposarcoma 12 50 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3382
MeSH 42 D008080
NCIt 47 C3194
UMLS 69 C0023827

Summaries for Liposarcoma

NIH Rare Diseases : 50 liposarcoma is a tumor that arises from fat tissue. this tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. their primary occurrence in the skin is rare. because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. the world health organization classification of soft tissue tumors recognizes 5 types of liposarcomas: well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. in the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. in general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. the patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. patients may report the following: associated episode of trauma to the region containing the mass painful swelling (occurs in one third of cases for as long as 6 mo) decreased function (ie, range of motion) numbness enlargement of varicose veins fatigue abdominal pain weight loss nausea vomiting  last updated: 6/23/2016

MalaCards based summary : Liposarcoma is related to mediastinum liposarcoma and intracranial liposarcoma, and has symptoms including fatigue, abdominal pain and nausea and vomiting. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include adipocyte, skin and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and behavior/neurological

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum.

Wikipedia : 71 Liposarcoma is a cancer that arises in fat cells in deep soft tissue, such as that inside the thigh or... more...

Related Diseases for Liposarcoma

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
id Related Disease Score Top Affiliating Genes
1 mediastinum liposarcoma 33.1 CDKN2A DES MDM2 VIM
2 intracranial liposarcoma 32.5 CD34 CDK4 DDIT3 FUS MB MDM2
3 liposarcoma of the ovary 32.4 CD34 CDK4 CDKN2A DDIT3 FUS HMGA2
4 aortic aneurysm 29.6 CDK4 CDKN2A MDM2
5 myxoid liposarcoma 12.4
6 larynx liposarcoma 12.0
7 kidney liposarcoma 12.0
8 retroperitoneal liposarcoma 12.0
9 pleomorphic liposarcoma 12.0
10 dedifferentiated liposarcoma 11.9
11 mixed liposarcoma 11.9
12 gastric liposarcoma 11.9
13 spindle cell liposarcoma 11.9
14 inflammatory liposarcoma 11.9
15 sclerosing liposarcoma 11.9
16 breast liposarcoma 11.9
17 myxoid liposarcoma of the ovary 11.9
18 liposarcoma of bone 11.8
19 vulvar liposarcoma 11.8
20 atypical lipomatous tumor 11.7
21 cellular myxoid liposarcoma 11.7
22 esophagus liposarcoma 11.7
23 cutaneous liposarcoma 11.7
24 adult liposarcoma 11.7
25 pediatric liposarcoma 11.7
26 fibroblastic liposarcoma 11.7
27 clear cell adenofibroma 10.3 CDKN2A TP53
28 rommen mueller sybert syndrome 10.3 CDK4 MDM2 TP53
29 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
30 lipoma 10.3
31 ovarian lymphoma 10.3 CD34 DDIT3
32 apocrine sweat gland neoplasm 10.3 CDK4 CDKN2A MDM2
33 endometrial squamous cell carcinoma 10.3 CDKN2A MDM2 TP53
34 extraosseous osteosarcoma 10.3 CDK4 DES MDM2
35 transverse colon cancer 10.3 EWSR1 FUS HMGA2
36 arteriosclerosis obliterans 10.3 CD34 TP53
37 cervical verrucous carcinoma 10.3 CDKN2A MDM2 TP53
38 bone leiomyosarcoma 10.3 CD34 CDK4 MDM2
39 uterine disease 10.3 CDKN2A HMGA2 TP53
40 amelogenesis imperfecta-gingival hyperplasia syndrome 10.3 CDK4 MDM2 MYOG
41 multifocal osteogenic sarcoma 10.2 CDK4 CDKN2A MDM2
42 inflammatory linear verrucous epidermal nevus 10.2 DES VIM
43 subacute leukemia 10.2 MB MYOG
44 pinta disease 10.2 CDK4 DDIT3 FUS MDM2
45 colorectal cancer 1 10.2 DDIT3 EWSR1 FUS
46 heart sarcoma 10.2 CDKN2A HMGA2 MYOG
47 endodermal sinus tumor 10.2 MB MDM2 TP53
48 extranodal nasal nk/t cell lymphoma 10.2 CDK4 CDKN2A EWSR1
49 heart leiomyosarcoma 10.2 DES MYOG
50 verruciform xanthoma of skin 10.2 DES MB TP53

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma

Symptoms & Phenotypes for Liposarcoma

Human phenotypes related to Liposarcoma:

32 (show all 9)
id Description HPO Frequency HPO Source Accession
1 fatigue 32 HP:0012378
2 abdominal pain 32 HP:0002027
3 nausea and vomiting 32 HP:0002017
4 subcutaneous nodule 32 HP:0001482
5 weight loss 32 HP:0001824
6 paresthesia 32 HP:0003401
7 abnormality of the kidney 32 HP:0000077
8 sarcoma 32 HP:0100242
9 varicose veins 32 HP:0002619

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 VIM
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.78 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.78 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.78 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 FUS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.78 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.78 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.78 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.78 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 FUS PPARG TP53 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 FUS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.78 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.78 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.78 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.78 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.78 PPARG
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.78 FUS TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.78 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 FUS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.78 FUS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 VIM

MGI Mouse Phenotypes related to Liposarcoma:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
2 cellular MP:0005384 10.29 CD34 CDK4 CDKN2A DDIT3 DES LRP1
3 cardiovascular system MP:0005385 10.24 CDKN2A DDIT3 DES LRP1 MB MDM2
4 homeostasis/metabolism MP:0005376 10.21 CD34 CDK4 CDKN2A DDIT3 DES LRP1
5 hematopoietic system MP:0005397 10.18 CD34 CDK4 CDKN2A DDIT3 LRP1 MB
6 growth/size/body region MP:0005378 10.17 CDK4 CDKN2A DDIT3 LRP1 MB MDM2
7 embryo MP:0005380 10.16 YBX1 CDK4 CDKN2A LRP1 MB MDM2
8 immune system MP:0005387 10.02 CD34 PPARG TP53 TSN VIM CDK4
9 adipose tissue MP:0005375 10 DDIT3 LRP1 MYOG PPARG TP53 TSN
10 integument MP:0010771 9.86 CD34 CDK4 CDKN2A MDM2 MYOG PPARG
11 liver/biliary system MP:0005370 9.76 YBX1 CDK4 CDKN2A DDIT3 LRP1 MDM2
12 muscle MP:0005369 9.65 MB MDM2 MYOG PPARG TP53 VIM
13 neoplasm MP:0002006 9.17 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARG

Drugs & Therapeutics for Liposarcoma

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Lenograstim Approved Phase 3,Phase 2 135968-09-1
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
22 Isophosphamide mustard Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
24 Liver Extracts Phase 3
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Antimitotic Agents Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 3,Phase 2
36 Pharmaceutical Solutions Phase 3
37 Anti-Allergic Agents Phase 3
38 Antipruritics Phase 3
39 Dermatologic Agents Phase 3
40 Histamine Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Neurotransmitter Agents Phase 3
44
Serotonin Phase 3 50-67-9 5202
45 Serotonin Agents Phase 3
46 Serotonin Antagonists Phase 3
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Palbociclib Approved Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
50
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999

Interventional clinical trials:

(show top 50) (show all 108)
id Name Status NCT ID Phase
1 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
3 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3
4 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
9 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
10 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
11 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
12 Selinexor in Advanced Liposarcoma Recruiting NCT02606461 Phase 2, Phase 3
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
15 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
16 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Active, not recruiting NCT01692678 Phase 3
17 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3
18 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
20 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2
21 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
22 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
23 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2
24 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2
25 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2
26 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2
27 Troglitazone in Treating Patients With Liposarcoma Completed NCT00003058 Phase 2
28 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2
29 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
30 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2
31 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2
32 Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Completed NCT00093080 Phase 2
33 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2
34 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
35 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
36 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
37 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
38 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
39 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2
40 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
41 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
42 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
43 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
44 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
45 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
46 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
47 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
48 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
49 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2
50 Ph II Cabazitaxel DD Liposarcoma Recruiting NCT01913652 Phase 2

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Genetic Tests for Liposarcoma

Anatomical Context for Liposarcoma

MalaCards organs/tissues related to Liposarcoma:

39
Adipocyte, Skin, Bone, Breast, Colon, Liver, Kidney

Publications for Liposarcoma

Articles related to Liposarcoma:

(show top 50) (show all 1262)
id Title Authors Year
1
Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report. ( 28092914 )
2017
2
Resection of giant mediastinal liposarcoma via 'a8L shape' incision. ( 28044001 )
2017
3
TP53INP2-related basal autophagy is involved in the growth and malignant progression in human liposarcoma cells. ( 28131096 )
2017
4
MRI characteristics associated with high-grade myxoid liposarcoma. ( 28256200 )
2017
5
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
6
Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. ( 28160093 )
2017
7
A newly emerged osteosarcomatous dedifferentiation of liposarcoma in lung metastasis - a potential diagnostic pitfall. ( 27879024 )
2017
8
Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. ( 27909788 )
2017
9
Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. ( 28177947 )
2017
10
Resectable primary pleural myxoid liposarcoma with a pedicle: report of a rare case and literature review. ( 28449500 )
2017
11
Liposarcoma metastases to the small bowel presenting as fat-density intraluminal lesions. ( 27920847 )
2016
12
Primary lesser sac myxoid liposarcoma: A case report. ( 27176503 )
2016
13
A Giant Retroperitoneal Liposarcoma Encasing the Entire Left Kidney and Adherent to Adjacent Structures: A Case Report. ( 27462239 )
2016
14
Mixed type retroperitoneal liposarcoma-combination of myxoid and well-differentiated type. ( 27072276 )
2016
15
Primary Diaphragmatic Dedifferentiated Liposarcoma in a Young Female Patient after Delivery. ( 27247814 )
2016
16
Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. ( 27016421 )
2016
17
The histological variants of liposarcoma: predictive MRI findings with prognostic implications, management, follow-up, and differential diagnosis. ( 27209201 )
2016
18
Myxoid liposarcoma with pleomorphic cells: Report of two cases with molecular confirmation of FUS gene rearrangements. ( 27515548 )
2016
19
Potential targeted therapeutic approaches in liposarcoma. ( 27085021 )
2016
20
Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas. ( 27028243 )
2016
21
Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma. ( 27822137 )
2016
22
Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. ( 28036291 )
2016
23
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. ( 27409346 )
2016
24
Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. ( 27597521 )
2016
25
Dedifferentiated Liposarcoma of Sigmoid Mesocolon - A Case Report. ( 27604671 )
2016
26
Retroperitoneal liposarcoma with different mimics: 2 case reports highlighting diagnostic challenges. ( 27773169 )
2016
27
Esophageal liposarcoma: Well-differentiated rhabdomyomatous type. ( 28035254 )
2016
28
Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. ( 27634478 )
2016
29
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. ( 26897615 )
2016
30
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. ( 27655679 )
2016
31
Retroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic factors. ( 27730802 )
2016
32
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. ( 27124835 )
2016
33
miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. ( 27157622 )
2016
34
High-Grade Myxoid Liposarcoma (Round Cell Variant) in a Dog. ( 27665042 )
2016
35
Liposarcoma: molecular targets and therapeutic implications. ( 27173057 )
2016
36
Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control. ( 27512857 )
2016
37
Primary mediastinal dedifferentiated liposarcoma resected by lateral thoracotomy with video-assisted thoracoscopic surgery. ( 26724326 )
2016
38
Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease. ( 26831007 )
2016
39
Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. ( 27746879 )
2016
40
Preoperative radiotherapy in the management of retroperitoneal liposarcoma. ( 27682864 )
2016
41
HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. ( 26595521 )
2016
42
Myxoid liposarcoma of the hand - A rare entity. ( 28018076 )
2016
43
MDM2 Expression in Extranodal Abdominal and Retroperitoneal Follicular Dendritic Cell Sarcomas, Mimicking Dedifferentiated Liposarcomas. ( 26180935 )
2016
44
Pericytic mimicry in well-differentiated liposarcoma / atypical lipomatous tumor. ( 27063472 )
2016
45
Lipoblastoma presenting as a rapidly growing paravertebral mass and masquerading as myxoid liposarcoma on fine needle aspiration cytology. ( 26919610 )
2016
46
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. ( 27893412 )
2016
47
Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. ( 26645460 )
2016
48
The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. ( 27043847 )
2016
49
Successful Re-resection for Locally Recurrent Retroperitoneal Liposarcoma at Four Years After ExA Vivo Tumor Resection and Autotransplantation of the Liver: A Case Report. ( 27320590 )
2016
50
Co-occurrence of a metastatic mammary liposarcoma and an ovarian sex-cord stromal tumor in a dog. ( 27892865 )
2016

Variations for Liposarcoma

Cosmic variations for Liposarcoma:

9 (show all 36)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10654 TP53 soft tissue,fat,liposarcoma,well differentiated c.637C>T p.R213* 11
2 COSM11059 TP53 soft tissue,fat,liposarcoma,well differentiated c.713G>A p.C238Y 11
3 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 11
4 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 11
5 COSM6901 TP53 soft tissue,fat,liposarcoma,well differentiated c.559+1G>A p.? 11
6 COSM10941 TP53 soft tissue,fat,liposarcoma,well differentiated c.730G>A p.G244S 11
7 COSM44512 TP53 soft tissue,fat,liposarcoma,well differentiated c.740A>G p.N247S 11
8 COSM11245 TP53 soft tissue,fat,liposarcoma,well differentiated c.430C>T p.Q144* 11
9 COSM44723 TP53 soft tissue,fat,liposarcoma,well differentiated c.674T>C p.V225A 11
10 COSM44094 TP53 soft tissue,fat,liposarcoma,well differentiated c.716A>G p.N239S 11
11 COSM43663 TP53 soft tissue,fat,liposarcoma,well differentiated c.826G>C p.A276P 11
12 COSM10646 TP53 soft tissue,fat,liposarcoma,well differentiated c.725G>A p.C242Y 11
13 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 11
14 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 11
15 COSM775 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.3140A>G p.H1047R 11
16 COSM12458 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1634A>C p.E545A 11
17 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 11
18 COSM25083 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1627A>G p.I543V 11
19 COSM21467 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1612G>A p.D538N 11
20 COSM760 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1624G>A p.E542K 11
21 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 11
22 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 11
23 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 11
24 COSM532 KRAS soft tissue,fat,liposarcoma,well differentiated c.38G>A p.G13D 11
25 COSM1290 KIT soft tissue,fat,liposarcoma,well differentiated c.1727T>C p.L576P 11
26 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 11
27 COSM487 HRAS soft tissue,fat,liposarcoma,well differentiated c.37G>A p.G13S 11
28 COSM480 HRAS soft tissue,fat,liposarcoma,well differentiated c.34G>A p.G12S 11
29 COSM720 FGFR3 soft tissue,fat,liposarcoma,well differentiated c.1949A>T p.K650M 11
30 COSM601 FGFR1 soft tissue,fat,liposarcoma,well differentiated c.374C>T p.S125L 11
31 COSM5676 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.122C>T p.T41I 11
32 COSM5708 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.119C>T p.T40I 11
33 COSM5743 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.117C>T p.A39A 11
34 COSM476 BRAF soft tissue,fat,liposarcoma,well differentiated c.1799T>A p.V600E 11
35 COSM1745010 MYOD1 soft tissue,upper leg,rhabdomyosarcoma,sclerosing c.365T>G p.L122R 4
36 COSM483 HRAS soft tissue,upper leg,malignant fibrous histiocytoma-pleomorphic sarcoma,myxoid c.35G>T p.G12V 4

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma

Expression for Liposarcoma

Search GEO for disease gene expression data for Liposarcoma.

Pathways for Liposarcoma

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1 12.54 CDK4 CDKN2A MDM2 PPARG TP53
2 12.33 CDKN2A HMGA2 MDM2 TP53 VIM
3 12.3 CDK4 CDKN2A MDM2 TP53 VIM
4
Show member pathways
12.26 CDK4 CDKN2A MDM2 TP53
5 12.25 CDK4 CDKN2A MDM2 TP53
6 12.17 CDK4 CDKN2A MDM2 TP53
7 12.14 DDIT3 EWSR1 FUS YBX1
8
Show member pathways
11.94 CDK4 CDKN2A MDM2 TP53
9 11.91 CDK4 CDKN2A MDM2 TP53
10 11.75 CDK4 CDKN2A MDM2 TP53
11 11.73 CDK4 MDM2 TP53
12 11.65 CD34 DES MYOG PPARG
13 11.62 CDKN2A MDM2 TP53
14
Show member pathways
11.62 CDKN2A MDM2 TP53
15 11.44 CDKN2A MDM2 TP53
16 11.42 DDIT3 EWSR1 FUS HMGA2 MDM2 PPARG
17 11.36 CDK4 MDM2 TP53
18 11.33 CDK4 MDM2 TP53
19 11.32 CDK4 CDKN2A MDM2 TP53
20 10.84 CDKN2A MDM2 TP53
21
Show member pathways
10.78 CDKN2A MDM2 TP53
22 10.76 CDK4 CDKN2A MDM2 TP53

GO Terms for Liposarcoma

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.85 CDK4 CDKN2A EWSR1 LRP1 MDM2 TP53
2 cytoplasm GO:0005737 9.5 CALB2 CD34 CDK4 CDKN2A DDIT3 DES
3 senescence-associated heterochromatin focus GO:0035985 9.16 CDKN2A HMGA2
4 protein-DNA complex GO:0032993 9.13 DDIT3 HMGA2 MYOG
5 nucleus GO:0005634 10.1 CALB2 CDK4 CDKN2A DDIT3 EWSR1 FUS
6 nucleoplasm GO:0005654 10.02 CDK4 CDKN2A DDIT3 FUS HMGA2 MDM2

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.97 DDIT3 HMGA2 MDM2 PPARG TP53 YBX1
2 cell cycle GO:0007049 9.91 CDK4 CDKN2A DDIT3 HMGA2 MYOG TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDKN2A DDIT3 HMGA2 MYOG PPARG TP53
4 positive regulation of gene expression GO:0010628 9.8 CD34 HMGA2 MDM2 TP53 VIM
5 negative regulation of transcription, DNA-templated GO:0045892 9.73 CDKN2A DDIT3 HMGA2 MDM2 PPARG TP53
6 positive regulation of apoptotic process GO:0043065 9.72 CDK4 CDKN2A HMGA2 PPARG TP53
7 negative regulation of neuron projection development GO:0010977 9.65 LRP1 MDM2 VIM
8 lipoprotein transport GO:0042953 9.57 LRP1 PPARG
9 negative regulation of telomerase activity GO:0051974 9.56 PPARG TP53
10 replicative senescence GO:0090399 9.55 CDKN2A TP53
11 ER overload response GO:0006983 9.54 DDIT3 TP53
12 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.52 DDIT3 TP53
13 positive regulation of cellular senescence GO:2000774 9.51 CDKN2A HMGA2
14 senescence-associated heterochromatin focus assembly GO:0035986 9.16 CDKN2A HMGA2
15 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
16 positive regulation of cell cycle arrest GO:0071158 8.8 HMGA2 MYOG TP53
17 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10 CDKN2A DDIT3 HMGA2 MYOG PPARG TP53

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.81 CDKN2A DDIT3 FUS HMGA2 MYOG PPARG
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.56 DDIT3 HMGA2 MYOG YBX1
3 transcription factor binding GO:0008134 9.43 CD34 CDKN2A DDIT3 HMGA2 PPARG TP53
4 identical protein binding GO:0042802 9.23 DES EWSR1 FUS MDM2 PPARG TP53

Sources for Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....